Comparison of Salivary Opiorphin in Burning Mouth Syndrome and Healthy Subjects and Its Correlation With Psychiatric Disorders

IF 1.7 Q3 DENTISTRY, ORAL SURGERY & MEDICINE Clinical and Experimental Dental Research Pub Date : 2024-12-01 DOI:10.1002/cre2.934

Zohreh Dalirsani, Maryam Amirchaghmaghi, Mahshid Malakuti Semnani, Mahdi Talebi, Seyed Isaac Hashemy, Mohammad Taghi Shakeri, Ava Taghizadeh

{"title":"Comparison of Salivary Opiorphin in Burning Mouth Syndrome and Healthy Subjects and Its Correlation With Psychiatric Disorders","authors":"Zohreh Dalirsani, Maryam Amirchaghmaghi, Mahshid Malakuti Semnani, Mahdi Talebi, Seyed Isaac Hashemy, Mohammad Taghi Shakeri, Ava Taghizadeh","doi":"10.1002/cre2.934","DOIUrl":null,"url":null,"abstract":"<div>\n \n \n <section>\n \n <h3> Objectives</h3>\n \n <p>Burning mouth syndrome (BMS) is a chronic disease in which the patient experiences a burning sensation in the oral mucosa without any pathological cause. Opiorphin is a pentapeptide that prevents pain and can have an antidepressant effect. The aim of this study was to evaluate salivary opiorphin concentration in BMS and healthy subjects. In addition, opiorphin concentration in BMS patients before and after psychiatric treatment was compared and the association between burning severity and psychiatric scores with salivary opiorphin concentration was examined.</p>\n </section>\n \n <section>\n \n <h3> Materials and Methods</h3>\n \n <p>This cross-sectional study included 28 BMS patients and 40 healthy individuals referred to the Department of Oral and Maxillofacial Medicine, Faculty of Dentistry, Mashhad, from September 2018 to August 2019. Patients with proven disease based on clinical and psychiatric examinations were included in the study. Unstimulated salivary opiorphin levels were assessed by ELISA. Statistical analysis was performed using SPSS version 24.</p>\n </section>\n \n <section>\n \n <h3> Results</h3>\n \n <p>Salivary opiorphin levels were significantly higher in BMS patients (2.16 ± 0.30 ng/mL) than in healthy subjects (1.80 ± 0.36 ng/mL) (<i>p</i> < 0.001). Opiorphin levels in BMS patients increased insignificantly after psychiatric therapy (<i>p</i> = 0.212). In addition, there was no significant association between opiorphin levels and age, gender, menopause, burning severity, anxiety, and depression status.</p>\n </section>\n \n <section>\n \n <h3> Conclusions</h3>\n \n <p>The opiorphin concentration in saliva is higher in BMS patients than in healthy subjects. Most BMS patients also suffer from anxiety and depression.</p>\n </section>\n </div>","PeriodicalId":10203,"journal":{"name":"Clinical and Experimental Dental Research","volume":"10 6","pages":""},"PeriodicalIF":1.7000,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/cre2.934","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical and Experimental Dental Research","FirstCategoryId":"1085","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/cre2.934","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"DENTISTRY, ORAL SURGERY & MEDICINE","Score":null,"Total":0}

引用次数: 0

Abstract

Objectives

Burning mouth syndrome (BMS) is a chronic disease in which the patient experiences a burning sensation in the oral mucosa without any pathological cause. Opiorphin is a pentapeptide that prevents pain and can have an antidepressant effect. The aim of this study was to evaluate salivary opiorphin concentration in BMS and healthy subjects. In addition, opiorphin concentration in BMS patients before and after psychiatric treatment was compared and the association between burning severity and psychiatric scores with salivary opiorphin concentration was examined.

Materials and Methods

This cross-sectional study included 28 BMS patients and 40 healthy individuals referred to the Department of Oral and Maxillofacial Medicine, Faculty of Dentistry, Mashhad, from September 2018 to August 2019. Patients with proven disease based on clinical and psychiatric examinations were included in the study. Unstimulated salivary opiorphin levels were assessed by ELISA. Statistical analysis was performed using SPSS version 24.

Results

Salivary opiorphin levels were significantly higher in BMS patients (2.16 ± 0.30 ng/mL) than in healthy subjects (1.80 ± 0.36 ng/mL) (p < 0.001). Opiorphin levels in BMS patients increased insignificantly after psychiatric therapy (p = 0.212). In addition, there was no significant association between opiorphin levels and age, gender, menopause, burning severity, anxiety, and depression status.

Conclusions

The opiorphin concentration in saliva is higher in BMS patients than in healthy subjects. Most BMS patients also suffer from anxiety and depression.

Abstract Image

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

求助全文

约1分钟内获得全文去求助

来源期刊

Clinical and Experimental Dental Research DENTISTRY, ORAL SURGERY & MEDICINE-

CiteScore

3.30

自引率

5.60%

发文量

165

审稿时长

26 weeks

期刊介绍： Clinical and Experimental Dental Research aims to provide open access peer-reviewed publications of high scientific quality representing original clinical, diagnostic or experimental work within all disciplines and fields of oral medicine and dentistry. The scope of Clinical and Experimental Dental Research comprises original research material on the anatomy, physiology and pathology of oro-facial, oro-pharyngeal and maxillofacial tissues, and functions and dysfunctions within the stomatognathic system, and the epidemiology, aetiology, prevention, diagnosis, prognosis and therapy of diseases and conditions that have an effect on the homeostasis of the mouth, jaws, and closely associated structures, as well as the healing and regeneration and the clinical aspects of replacement of hard and soft tissues with biomaterials, and the rehabilitation of stomatognathic functions. Studies that bring new knowledge on how to advance health on the individual or public health levels, including interactions between oral and general health and ill-health are welcome.